Education
About Us
Working with TipRanks
Follow Us
Better Therapeutics, Inc. (BTTX)
:BTTX
BTTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume65.57K
Average Volume (3M)350.25K
Market Cap
$10.87K
Enterprise ValueN/A
Total Cash (Recent Filing)-$757.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta210.61
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding54,352,497
10 Day Avg. Volume286,441
30 Day Avg. Volume350,249
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Better Therapeutics News
PremiumCompany Announcements
Better Therapeutics Overhaul and Nasdaq Delisting
PremiumCompany Announcements
Better Therapeutics Issues Investor Presentation with Cautions
PremiumCompany Announcements
Better Therapeutics CEO Discusses Future on Bloomberg TV---
Options Prices
Currently, No data available
---
Ownership Overview
35.69%
Insiders
0.13% Other Institutional Investors
99.87% Public Companies and
Individual Investors
BTTX FAQ
What was Better Therapeutics, Inc.’s price range in the past 12 months?
Better Therapeutics, Inc. lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Better Therapeutics, Inc.’s market cap?
Better Therapeutics, Inc.’s market cap is $10.87K.
When is Better Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Better Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Better Therapeutics, Inc. overvalued?
According to Wall Street analysts Better Therapeutics, Inc.’s price is currently Overvalued.
Does Better Therapeutics, Inc. pay dividends?
Better Therapeutics, Inc. does not currently pay dividends.
What is Better Therapeutics, Inc.’s EPS estimate?
Better Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Better Therapeutics, Inc. have?
Better Therapeutics, Inc. has 54,352,497 shares outstanding.
What happened to Better Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Better Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BTTX
---
Company Description
Better Therapeutics, Inc.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
---
BTTX Stock 12 Month Forecast
Average Price Target
―Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Protagenic Therapeutics
―
---